Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
| Autor: | Onder Tonyali, Ahmet Alacacioglu, Faysal Dane, Halit Karaca, Özlem Sönmez, Umut Demirci, M. Ali Kaplan, Hakan Harputluoglu, Alper Sevinc, Nuriye Ozdemir, Bilge Aktas, Tulay Akman, Ozan Balakan, Ugur Coskun, Hüseyin Engin, Yusuf Gunaydin, Suleyman Buyukberber, Gulnihal Tufan, I. Tugba Unek, Mustafa Benekli |
|---|---|
| Přispěvatelé: | Zonguldak Bülent Ecevit Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Malignant glioma Cancer Research medicine.medical_specialty Bevacizumab Combination therapy Antibodies Monoclonal Humanized Irinotecan Young Adult Recurrence Internal medicine Glioma Antineoplastic Combined Chemotherapy Protocols medicine Recurrent disease Humans neoplasms Aged Neoplasm Staging Retrospective Studies Hematology business.industry Treatment options General Medicine Middle Aged medicine.disease Treatment Outcome Multicenter study Disease Progression Camptothecin Female Neoplasm Grading business Follow-Up Studies medicine.drug |
| Popis: | Purposes: The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy. Methods: A total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6). Results: Bevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1-37), and median follow-up was 6 months (range 1-36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5-9.5) and 6 months (95 % CI 4.9-7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1-10.9) and 8 months (95 % CI 6.6-9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages. Conclusions: Present study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors. © 2013 Springer-Verlag Berlin Heidelberg. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|